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The Reticulum Cell Sarcoma (RCS)' is a spontaneous lymphatic tumor of the
SJL/J (H-29) mouse, first observed by Murphy (1) in upwards of90% of SJL/J mice
ofamean age of 13 .3 mo. RCS tumors areconsidered B cell lineage neoplasms that
exhibit IgH chain gene rearrangements, butno surface or cytoplasmic Ig (2) . Addi-
tionally, RCS tumors express IAs MHC-encoded polypeptides (3) . RCS tumors re-
quire an obligate syngeneic host CD4+ T cell response for growth (4, 5) . The in
vivo passive administration ofGk1.5 mAb (anti-CD4) or haplotype-specific anti-Ia
antibody to SJL/J mice, before or shortly after transfer of the transplantable RCS
line, RCS LA-12, resulted in the complete abrogation of tumor growth (5, 6) .
The nature of the RCS tumor-associated antigen responsible for the stimulation
of syngeneicT cell proliferation has remained elusive . However, Katz et al . (7) made
the observation that both the in vivo growth of RCS and the in vitro RCS-specific
T cell response correlated with the lack ofIE expression . Studies by Wilbur et al .
(8, 9) further implicated the role ofIE in tumor growth . Furthermore, two of four
RCS-specific T cell hybridomas when cocultured with IEd- or IEk-bearing allogeneic
spleen cells were stimulated to release T cell growth factors, such as IL-2 (10) .
Recently, Kappler et al . (11) have developed an mAb, termed KJ23a, which
specifically interacts with TCR containing the V0 17a variable segment gene prod-
ucts . Interestingly, only mice that lack thymic IE exhibit KJ23a+ T cells in the pe-
riphery, since V017a expression confers IE reactivity and are deleted by IE-expressing
mice (12) . SJL/J (IE- ) mice possess KJ23a+ T cells in their periphery. Since the
RCS tumors stimulateT cells that appear to recognize "IE-like" antigens and IE+
Fl mice failed to support RCS tumor growth, we undertook studies to examine the
role that V(317a+ (KJ23a+ ) T cells may play in the RCS-specific T cell response .
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SJL/J T CELL RESPONSE TO RETICULUM CELL SARCOMA
Evidence is presented that supports a major role for KJ23a+ T cells in the response
to both spontaneous and transplantable RCS tumors.
Materials and Methods
Mice.
￿
Female SJL/J, DBA/2, and BALB/c mice (6-8 wk) were purchased from TheJackson
Laboratory, Bar Harbor, ME. BALB/c nu/nu mice were bred in the nude mice facility at
UCLA, Los Angeles, CA.
Medium.
￿
All cultures were performed in high glucose formula DMEM (Gibco Laborato-
ries, Grand Island, NY) supplemented with 10% FCS (Gemini Bio-Products, Calabasas, CA),
sodium pyruvate, nonessential amino acids, L-glutamine, penicillin, streptomycin (all from
Gibco Laboratories), and 5 x 10-5 M 2-ME (Sigma Chemical Co., St. Louis, MO).
mAbs.
￿
The KJ23-588.1 (KJ23a), MIgG2a, hybridoma specific for Vp17a TCRbearing
T cells, as described (11), was the generous gift of Drs. P. Marrack and J. Kappler (National
Jewish Center for Immunology and Respiratory Medicine, Denver, CO). KJ23a mAb was
purified from ascites fluid of BALB/c mice using protein A-agarose (Bio-Rad Laboratories,
Richmond, CA). F23 .1.R2 (F23.1), MIgG2a, hybridoma specific for V(D8 TCRbearing T
cells, as described (13), was the generous gift of Dr. E. Sercarz (UCLA, Los Angeles, CA).
F23.1 was purified from ascites fluid ofBALB/c nu/nu mice using protein A chromatography
as described (14). Gk1.5, Rat IgG2a, hybridoma specific for CD4 (L3T4), as described (15),
was purchased from American Type Culture Collection, Rockville, MD (TIB 207). Gk1.5
was used as an ascites fluid obtained from BALB/c nu/nu mice. HO-13-4, MIgM, specific
for Thy1.2 T cells, as described (16), was purchased from American Type Culture Collection
(TIB 99) and used as an ascites fluid obtained from BALB/c nu/nu mice.
RCS Tumorand TumorPurification.
￿
The transplantable RCS line, RCS LA-12, used in the
present studies arose spontaneously in a female SJL/J mouse and was established as a trans-
plantable line in our laboratory. This tumor was maintained in vivo by intraperitoneal pas-
sage of 107 viable cells in young SJL/J mice. Spontaneous primary tumors were obtained
from mesenteric lymph nodes of 14-15-mo-old female SJL/J mice. RCS single cell suspen-
sions were made from excised tumorous mesenteric lymph nodes (8-14 d after inoculation
for RCS LA-12), and separated from B cells and macrophages on a nylon wool column. T cells
were removed by the use of HO-13-4 and low-tox rabbit complement (Cedarlane Laborato-
ries, Hornby, Ontario), 1 :10, followed by isolation of RCS on Ficoll-Hypaque density-gradient
centrifugation as previously described (17) .
IL-2 Production by RCS-speck TCell Hybridomas.
￿
RCS-specific T cell hybridomas and the
IL-2 production assay were described previously in (10). Briefly, 2 x 105 hybridoma cells
were cocultured with 105 glutaraldehyde-fixed (0.01%) RCS or 106 'Y-irradiated (2,000 rad)
SJL/J spleen cells in 200 ul of complete medium at 37°C for 24 h in a humidifying C02
incubator. 50 wl ofsupernatant from each well was transferred to microtiter plates containing
5 x 103 CTLL-2 and incubated at 37°C for 16-20 h. CTLL-2 cells were then pulsed with
1 uCi of [3H]TdR for an additional 8 h, after which cells were MASH harvested onto glass
fiber filters (W. A. Bioproducts, Walkersville, MD) and [3H]TdR incorporation was assessed
in the presence of 1 .0 ml of Safety-sol II scintillation fluid (Research Products International,
Mt. Prospect, IL) usinga beta counter. [3H]TdR incorporation is expressed in cpm t SD.
CTLL-2 Line.
￿
The IL-2-dependent CTLL-2 cell line, as described (18), was purchased
from American Type Culture Collection (TIB 214) and maintainedin 9 partscomplete medium
and 1 part rat Con A supernatant as a source of IL-2.
SJL/J Spleen T Cells and the Mixed Lymphocyte Tumor Interaction (MLTI) and MLR Cul-
tures. Splenic T cellsfrom 8-12-wk-old SJL/Jmice were purified as described (8). For MLTI
cultures, 5 x 105 SJL/J T cells were incubated with 5 x 10' y-irradiated RCS (10K R) in
a totalvolume of 200 ul complete medium, in 96-well flat bottomed plates. The cultures were
then incubated for 96 h at 37°C in a humidifying 10% C02 incubator. A 1.0 gCi pulse of
[3H]TdR was added to each well during the last 24 h, after which the plates were MASH
harvested and [3H]TdR incorporation was assessed. For MLR cultures, 5 x 105 SJL/J T cells
were incubated with 5 x 105 y-irradiated (2,000 rad) autologous SJL/J spleen cells. For
fluorocytometric analysis parallel 0.8-ml MLTI cultures were performed in 24-well clusterKATZ ET AL .
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dishes (Costar, Cambridge, MA) . The viable cells were collected on Ficoll-Hypaque gradients
and analyzed after antibody staining by flow cytometer.
mAb MediatedInhibition ofIL-2 Production by T Cell Hybridomas and T Cell Proliferation.
￿
Inhi-
bition assays using affinity-purified monomeric KJ23a were performed analogous to inhibi-
tion assays described (10) . Briefly, IL-2 production and T cell proliferation assays were per-
formed as described above, except 10 wg/ml filter-sterilized affinity-purified monomeric KJ23a
mAb was added at the initiation ofeach culture . Monomeric KJ23a was obtained by ultra-
centrifugation of 200 gg/ml affinity-purified KJ23a at 35,000 rpm in an SW50 .1 rotor at 4°C
for 1.5 h . The resulting supernatant was collected and sterilized by filtration through 0.22
wM filter (Gelman Sciences, Inc ., Ann Arbor, MI) . The nonreactive mAb F23 .1 was treated
similarly and added in parallel as a negative control . Inhibitionby KJ23a ofIL-2 production
was expressed relative to the IL-2 production by the hybridomas in the presence of F23 .1 mAb .
Fluorocytometric Analysis.
￿
For single-color analysis of T cells and T cell hybridomas, 106
cells were incubated with 20 gg of affinity-purified KJ23a or F23 .1, or 25 Rg of Gk1.5 ascites
in 200 ul in 3% FCS/HBSS on ice for 30 min . Afterwards, the cells were washed twice in
ice-cold 3% FCS/HBSS . Gk1.5-labeled cells were then incubated with a 1 :100 dilution of FITC-
conjugated goat anti-rat IgG, F-GAR, (Jackson ImmunoResearch, Avondale, PA) for 30 min
on ice . KJ23a- or F23 .1-labeled cells were incubated with 1:100 dilution of FITC-conjugated
goat anti-mouse IgG, FGAM, (Cappel Laboratories, Cochranville, PA) for 30 min on ice .
Afterward, the cells were washed thrice in ice-cold 3% FCS/HBSS and resuspended in 1.0
ml of1% paraformaldehyde (Sigma Chemical Co.), 0.1% NaN3 in PBS (fix solution) . Cells
were then analyzed on an EPIC-C flow cytometer. For two-color analysis, 106 T cells were
incubated with one or more of the above-mentioned primary antibodies for 30 min on ice .
The cells were then incubated for 30 min on ice with 200 wl of a two-color fluorochrome
cocktail containing, 1:100 dilution of FGAR and 1:50 dilution of phycoerythrin-conjugated
goat anti-mouse IgG, PE-GAM (Tago Inc., Burlingame, CA), which had been previously
adsorbed to rat IgG to remove crossreactivity . The cells were then washed and fixed as above .
The cells were analyzed by dual-color parameters on an EPIC-C flow cytometer. In all ex-
periments, cells were incubated with only the fluorochrome-coupled secondary antibody(s)
as a control for background fluorescence and to establish size gates . Two-color analysis is
displayed at 2, 8, and 16% map levels in Figs . 1 and 2 .
Results
RCS Tumor-specific T Cell Hybridomas Express V(317a-bearing 7LR.
￿
In a previous
study, we have characterized four RCS-specific T cell hybridoma clones (10). Two
hybridomas, IF8-11-2 and 2D5-3-3, were RCS specific and released IL-2 onlywhen
cocultured with RCS tumors . The other two hybridomas, 45-2-4 and 1A4-6, released
IL-2 when cocultured with RCS or IE+ allogeneic spleen cells . Because of this re-
sponse to IE-bearing cells, we examined whether the hybridomas were expressing
V(317a-bearingTCR . Fluorocytometric analysis revealed that all four T cell hybrid-
omas stained positively with KJ23a (antiVo17a) and were negative for the control
mAb F23.1 (antiV(38) (data not shown) . To corroborate these findings, we tested
whether monomeric KJ23a mAb would inhibit the RCS-stimulated release of IL-2
by the hybridomas . As seen in Table I (Exp . 1), KJ23a inhibited by >90% the re-
lease of IL-2 by the hybridomas in the presence ofRCS; F23.1 had no effect . Fur-
thermore, KJ23a inhibited the allo-stimulatory response of 45-2-4 to DBA/2 spleen
cells (Table I, Exp . 2) . These results demonstrate that all four RCS-specific T cell
hybridomas bear V017a-containing TCR . Furthermore, these results indicated that
the same R chain of the TCR is involved in both the RCS and allogeneic response
by 45-2-4 .
The Syngeneic Proliferative Response, In Vitro, to RCS Is Predominantly Mediated by CD4+
V/317a+ T Cells.
￿
To address the role ofKJ23a+ T cells in the generation of the syn-1556
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TABLE I
Inhibition of RCS-speck T Cell Hybridoma Secretion of IL-2 in the Presence of KJ23a mAb
[ 3H]TdR incorporation as measured with the IL-2-dependent CTLL-2 cell line . CTLL-2 proliferation in
the absence ofIL-2 was <500 cpm, while in the presence of IL-2 (rat ConA supernatant 1 :10) it was 71,500
cpm . Percent inhibition (in parentheses) by KJ23a of IL-2 production was expressed relative to the IL-2
production by the hybridomas in the presence of F23 .1 mAb .
x RCS LA-12 stimulator cells were fixed with 0.01% glutaraldehyde and did not release measurable IL-2 .
S Assay was performed as above, except 10 6 y-irradiated DBA/2 (IEd ) spleen cells were used as stimulator
cells . DBA/2 cells alone did not release measurable amounts of IL-2 .
geneic proliferative response to RCS, we performed MITI cultures in the presence
and absence ofKJ23amAb. SyngeneicMLR cultures were maintained in parallel,
usingautologous spleen cells, as a control for nonspecific proliferation . In the pres-
ence of 10 ug/ml ofKJ23a mAb, the SJL/JT cell proliferative response was markedly
inhibited from 25 to 76% (Table II) . The control F23.1 mAb had no effect . The
effective blocking by KJ23amAbwasnot restricted to the particular RCSline used,
in that the proliferative response of SJL/J T cells to spontaneous primary mesen-
teric RCS tumors, RCS Sp-3, RCS Sp-4, and RCS Sp-7, was also significantly in-
hibited by KJ23a (Table II, Exp . 2 and 3) . The inhibition ofT cell proliferation
by KJ23a to both spontaneous and transplantable tumor was similar, suggesting
that both the spontaneoustumors and the transplantableRCS LA-12 stimulate pre-
dominantly the same T cell subset, namely V/317a' T cells .
Since mAb directed to V017a TCR significantly inhibited the proliferative re-
Exp . Hybridoma (2 x 10 5 ) Stimulator (10 5) mAb (10 pg/ml) [3H]TdR incorporation"
cpm t SD
1 45-2-4 RCS (LA-12)t - 36,666 t 639
KJ23a 1,322 t 146 (96.4)
F23 .1 34,175 t 4,225
Con A (10 pg/ml) - 45,280 t 1,464
- - 31511
2D5-3-3 RCS - 35,825 t 6,351
KJ23a 1,701 t 393 (95 .2)
F23 .1 32,007 t 7,229
Con A - 29,219 t 3,136
- - 503 t 85
1A4-6 RCS - 26,571 f 4,885
KJ23a 1,957 t 778 (92 .6)
F23 .1 20,519 t 684
Con A - 53,538 t 3,536
- - 220 t 165
IF8-11-2 RCS - 78,032 t 1,019
KJ23a 3,056 t 918 (96.0)
F23 .1 67,239 t 906
Con A - 80,250 f 643
- - 1,661 t 461
2 45-2-4 DBA/2 spleens 23,542 t 1,946
KJ23a 1,300 t 766 (94 .9)
F23 .1 26,804 f 1,688
Gk1 .5 2,876 t 425
14-4-4s 5,583 t 1,384KATZ ET AL.
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TABLE II
Inhibition of RCS-speck T Cell Proliferation by KJ23a mAb
Cultures are incubated at 37° for 72 h, whereupon the cultures are pulsed with 1 RCi of [ 3H]TdR for 24 h
and then harvested by MASH . Proliferation is expressed in cpm t SD of triplicate cultures .
1 Monomeric affinity-purified mAbs were added at the initiation of each culture at 10 Vg/ml .
s 5 x 104 y-irradiated RCS or 5 x 10 5 y-irradiated SJL/J spleen cells were cocultured with 5 x 10 5 SJL/J
T cells in complete medium .
sponse ofT cells to both spontaneous andtransplantable RCS, we determined quan-
titatively the frequency of the responding V017a+ T cells in theT cell blast popu-
lation . TCRspecific mAbstaining was enumerated usingPE-coupled goat anti-mouse
IgG(red), while the CD4-specific staining wasmonitoredby FITC-conjugated goat
anti-rat IgG (green) . As seen in Fig . 1 A, the initial T cell population on day 0
was 56% CD4+ T cells (the sum of quadrants 2 and 4) ofwhich 9% were double
positive for KJ23a and Gk1.5 (quadrant 2 only) . Furthermore, the T cells were of
uniform size as determined by forward angle and 90° angle light scatter (data not
shown) . However, after 4d of culture with the transplantable RCS LA-12 line, the
T cells were 66% double positive for KJ23a and Gk1.5, when analyzed as a whole
population (Fig . 1 B) . Further, if only the blast population was analyzed, the resul-
tant double-labeled T cells represented >80% of the total blast cells (Fig. 1 C) .
Moreover, all the Gk1.5 + T cells in the blast population were also KJ23a+ ; thus,
virtually all of the CD4+ T cell blasts generated in response to RCS LA-12 were
V017a+ T helper cells.
When theMITI cultures were effected usingy-irradiated spontaneousRCS tumors
as stimulator cells, we obtained comparable results with those seen using the RCS
LA-12 line . As seen in Fig. 2 A, two-color analysis of day 4T cells cocultured with
the spontaneousRCS tumor, RCS Sp-3, shows that 47% of the total cells were both
KJ23a+ and Gk1.5+ . Interestingly, as seen above with T cells cultured with RCS
LA-12, two populations ofCD4+ T cells were observed after coculture with RCS
Sp-3 ; aCD4 dim population, which represented27% of the total cells (36.4 of the
total CD4+ T cells), and a CD4+ bright population, which was 47% of the total
cells (63.5% of the total CD4+ cells) . All of theCD4 bright cells were also KJ23a+,
and represented blast cells asjudged by forward angle and 90° angle light scatter
(datanot shown) . These results demonstrate that both spontaneous and transplant-
able RCS tumors stimulate a similar and marked proliferation ofKJ23a+ T cells .
The Responsive Syngeneic RCS-speck T Cells in Tumor-bearing Mice Are Predominantly
KJ23a' . The RCS LA-12 line was passed intraperitoneally (5 x 103 cells) in 8-
wk-old SJL/J mice, and 14 d later, tumor-bearing mesenteric lymph nodes were re-
Exp . Stimulator cells None
[3H]TdR incorporation"
KJ23a mAbl F23 .1 mAb
cpm t SD
1 RCS LA-12 30,967 t 2,920 8,877 t 350 27,418 t 1,579
2 RCS Sp-4 - 17,889 t 1,514 67,233 t 9,609
RCS Sp-7 - 11,556 t 1,539 46,811 t 6,017
SJL/J spleen 502 t 206 - -
3 RCS LA-12 49,099 t 4,261 39,345 t 400 52,823 t 1,687
RCS Sp-3 32,836 t 1,689 24,267 t 5,033 43,360 t 721
None - 566 t 215 86 ± 21558
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Two-color analysis of SJL/J spleen T cells cocultured with RCS tumor. Tcellswere
incubated with KJ23a(mouse IgG2a) andGkl.5 (rat IgG2a), washed, and then incubated with
FITC-conjugated goat anti-rat IgG(F-GAR) to labelGk1.5 andphycoerythrin-conjugated goat
anti-mouse IgG (PE-GAM) to label KJ23a. PE-GAM was pre-adsorbed on rat IgG sepharose
to remove anti-rat IgG crossreactivity. Controlstaining andanalysis usingonly thefluorochrome-
conjugated secondary reagents were performed to set the red and green gains, size gates, and
quadrant lines(datanot shown). (A)The initial splenicTcell population was 56% CD4' (quad-
rants 2 and 4) and 9% double positive for KJ23a and CD4 (quadrant 2). (B) Total splenic T
cells after a 4-d MLTI coculture with RCS LA-12. 66% of the total SJL/J T cells labeled with
KJ23a and brightly with Gk1.5 (quadrant2), 20% of the T cells labeled dimly with Gk1.5 and
were negative forKJ23a(quadrant 4). (C) Blast SJL/J splenicTcellsafter a 4-d MLTI stimula-
tion by the transplantable RCS LA-12 line. Blast cells were elucidated by limiting analysis to
cellsthat exhibitedboth increased forward and901anglelightscatterover apopulation of inacti-
vated SJL/Jspleen Tcells(datanot shown). Double labeling with KJ23aandGk1.5 stained 81%
ofblastcells(quadrant2). Only 8% of theGk1.5 blastTcells were notKJ23apositive (quadrant4).
moved and analyzed by two-color fluorocytometry. As seen in Fig. 2 B, CD4+ T
cellsrepresent 51 % of the total cells in thenylon wool-nonadherent fraction (T cells
and RCS tumor). Further, 70% of the CD4+ T cells were also positively stained
by KJ23a. This is comparable with the number of V(317a' T cells found in the in
vitro MLTI cultures (Fig. 1, B and C). Furthermore, the KJ23a+ T cells were also
brightly stained by Gk1.5 . The remaining dull CD4' T cells (30° Io of the total
CD4+ cells) were KJ23a- (Fig. 2 B). We therefore conclude that V(317a+ T cells
play an important role in responding to RCS stimulation in vivo.
FIGURE 2.
￿
Two-coloranalysis oftotal
spleen T cells in response to sponta-
neous RCS tumor, RCS Sp-3, and T
cells from tumor-bearing MLN. (A)
Total splenicTcellsafter a 4-dMLTI
coculture with the spontaneous RCS
tumor, RCS Sp-3 . 47% of the total
SJL/J Tcells were double positive for
KJ23aandGK1.5. TheGk1.5 dimcells
were negative for KJ23a (27%). (B)
Nonadherent cells from tumor-bearing
MLN of mice given RCS LA-12 14 d
prior. 51% of the nonadherent cells
were Gk1.5' . 70% oftheGk1.5' cells
were also stained by KJ23a.KATZ ET AL.
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Discussion
Evidence is presented here that demonstrates the majority of the syngeneic cells
responding to both primary spontaneous RCS tumors andtransplantable RCS LA-
12 are CD4' V017a' T cells. Several lines of evidence support this conclusion. All
four RCS-specific T cell hybridoma clones are V017a' and show marked inhibi-
tion ofIL-2 release in the presence of KJ23amAb. Secondly, the response of SJL/J
T cellsto both spontaneous and transplantable RCS was markedly inhibited by the
addition of monomeric KJ23a. The T cell proliferative response was inhibited on
average by 54%, despite the fact that VD17a+ T cells represent only 7-9% of the
total splenic T cells in SJL/J mice. Third, we analyzed by flow cytometry the SJL/J
T cells after a 4-d stimulation by either spontaneous or transplantable RCS, and
found significant expansion of the KJ23a* T cells from an input level of 9% to as
high as 84% of thetotal blast population. Concordantly, thesecells were bright staining
for CD4 (L3T4). The dim staining L3T4' T cells were devoid of KJ23a+ cells, sug-
gesting that all of the KJ23a+ cells responded to RCS by developing into blast T
cells. Lastly, we analyzed the phenotype of T cells from tumor-bearing mesenteric
lymph nodes, and found that the majority of the CD4+ T cells responding to RCS
were KJ23a* . Therefore, it appears that the in vivo response was comparable with
that seen in vitro. These findings represent the first demonstration of a striking ex-
pansion of T cells bearing a single VP TCR family in response to a spontaneous
tumor. Furthermore, these results support the notion that the RCS tumors carry
IE or "IE-Like" tumor-associated antigens.
Kappler et al. (11) found that TCR that use the V017a variable segment gene
product react with high frequency to the IE class II MHC molecules. This bias to-
wards IE recognition by V017a' T cells was independent of the coexpressed a chain
of the TCR (11) . Further, mice that demonstrate intrathymic expression of IE were
shown to selectively delete V017a' cells during T cell maturation (12). Interestingly,
previous studies using F1 hybrid mice from matings of either SJL/J and congenic
mice, or SJL/J and recombinant congenic mice found that both the in vivo growth
of RCS and the in vitro RCS-specific T cell response correlated inversely with IE
expression. In fact, F1 mice that expressed IE failed to grow or respond to the
tumor. This negative effect could not be overcome by increasing either tumor in-
oculum or by increasing the assayperiods (7). Thus, in light oftheevidence presented
here and that IE-expressing mice debate V(317a+ T Cells, it seems attractive to spec-
ulate that the failure of IE-expressing Fl mice to support the growth of and respond
to RCS is the result of the deletion of V017a' T cells in these mice.
The predominant role played by VR17a+ T cells in the response to RCS suggests
a potential therapeutic role for KJ23a mAb in the intervention and prevention of
RCS tumors in SJL/J mice. Treatment of SJL/J mice with KJ23a mAb may result
in the complete inhibition of RCS growth. Further, the prophylactic treatment of
aged mice with KJ23a may prevent the onset of spontaneous RCS tumors. These
approaches, while not radically different from ourprevious studiesusing Gk1.5 (5),
have several advantages. KJ23a mAb affects only a portion of the CD4 subset and
not the whole CD4 population, thereby not crippling the host's ability to mount
protective humoral and cellular immunity. Furthermore, unlike Gk1.5, the KJ23a
mAb is of mouse origin, which should allow for a slower clearance rate and would
not elicit a potentially fatal anti-rat Ig response, as has been seen upon repeated1560
￿
SJL/J T CELL RESPONSE TO RETICULUM CELL SARCOMA
administration ofrat IgG. Therefore, KJ23aappears to possessthe intriguing potential
as a tumor-specific therapeutic strategy in SJL/J mice .
ThetwoRCS-specific hybridomas, 178and 2D5, shown previously not to be stimu-
lated by allo-IE, were nonetheless KJ23a+ . While we have not observed IL-2 re-
lease by IF8 or 2D5 in the presence ofanumber of allogeneic stimulator cells, IF8
and 2D5 have exhibited specific binding to allo-IE spleen cells (IEd, IE'), which was
inhibitable by anti-IEmAb of defined specificities (unpublished observation). We
are currently investigating whether the specific binding, while not leading to IL-2
release, maytrigger other initial activation events, such as the mobilization of cyto-
plasmic Cat+ . Further, we have clearly not exhausted all possible allogeneic IE+
strains, therefore, there may still be allogeneic strains that bind and stimulate 1F8
and2D5. However, the fact that IF8 and 2D5 are KJ23a+ and do not release IL-2
upon stimulation by the allo-IE strains tested to date, still remains an enigma.
While the reactivity of V(317a+ T cells from SJL/J mice to IE appears to be
greatest for allogeneic IE, there is a significant reactivity ofV017a+ T cells for self
IE (19) . SJL/J mice lack expression of the as heterodimer of IE due to a 600-bp
deletion in the promoter and leader sequence of the Ea gene (20, 21) . ED, however,
is actively transcribed (20) . The nature of the IE-like determinant on SJL/J RCS
tumors remains unknown. However, experiments usingL cells transfected with Ea
and AD genomic DNA have demonstrated that cell surface expression ofEa and
AD is possible, in what are termed mixed isotype heterodimers (22, 23) . Therefore,
it remains a formal possibility that ED' is expressed with Aas in a mixed hetero-
dimeron the surface ofRCS tumors . SJL/JTcells, which are nottolerant to surface
expression of ERs, would therefore respond to it . Evidence presented here would
suggest that this response would be predominantly by KJ23a+ T cells. Alternatively,
cytoplasmic ED' protein, unable to achieve surface expression, is degraded by the
RCS tumor cells and presented by IA' in peptide form . While no direct evidence
exists that the presentation of ED peptide by IA' would elicit a KJ23a+ T cell re-
sponse, recent evidence suggests that allo-reactive CTL clones can recognize allo-
MHC class I peptide in the context ofself-MHC class I, and thereby reconstitute
the allogeneic response (24) . Therefore, it remains to be tested whether RCS tumors
may process and present ERs in the context of IA'.
Recent evidence suggests that KJ23a+ T cells recognize and respond to IE only
when complexed with aB cell-specific peptide (25) . RCS, aBcell tumor, stimulates
a vigorous KJ23a+ T cell response, and therefore, may express this B cell stimula-
tory antigen . The expression of such an antigen by RCS may explain the observed
stimulation of RCS-specific T cell clones by activated syngeneic blast B cells (4).
The exact nature, though, of the RCS tumor-associated antigen awaits future ex-
perimentation .
Summary
Previous studies have revealed that the reticulum cell sarcoma (RCS) of SJL/J
(H-2g, IE- ) mice express an "IE-like" stimulatory tumor-associated antigen, the ex-
pression ofwhich is requisite forstimulatinghostT cells necessary fortumorgrowth .
Herein, we present evidence that the predominantT cells raised in the syngeneic
response to both spontaneousand transplantable RCStumors are of the V017aTCR
clonotype . The VS17a+ clonotype ofT cells has been shown to interact with IE al-KATZ ET AL.
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logeneic specificities. We demonstrate that all four characterized RCS-specific T cell
hybridomas stained positively for the antiVO17a mAb, KJ23a. Additionally, KJ23a,
when added to cocultures of the T cell hybridomas and RCS tumors, inhibited the
release of IL-2 by the hybridomas. Further, KJ23a was shown to markedly inhibit
the proliferation ofSJL/J T cells when cocultured with either spontaneous or trans-
plantable RCS tumor cells. When analyzed by flow cytometry, the T cell blast popu-
lation raised in response to both spontaneous and transplantable RCS were >80%
KJ23a+ . These T cells were brightly stained by the anti-CD4 mAb, Gk1.5, and,
therefore, represent class II-responsive T cells. In corroboration ofthe in vitro data,
T cells derived from mesenteric lymph nodes ofRCS tumor-bearing mice had like-
wise undergone a similar expansion of VS17a+, CD4` T cells. Together, these
results indicate that KJ23a+ T cells play an important and predominant role in the
response of SJL/J mice to spontaneous RCS tumors and provide further suggestive
evidence that the stimulatory antigen(s)on the RCS tumoris IE or an "IE-like" mol-
ecule. Significantly, the important role V017a+ T cells play in the response to RCS
suggests a potential therapeutic role for KJ23a mAb in the intervention and preven-
tion of RCS tumors in SJL/J mice.
We wish to thank Drs. J. Kappler and P Marrack for their generous gift of the KJ23a mAb
and for critical review of the manuscript; Dr. E. Sercarz for the kind gift of the F23.1 mAb
used in this study; and Drs. M. Kronenberg and J . Braun for their critical review of this
manuscript.
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